Predict your next investment

Viome company logo
Corporation
HEALTHCARE | Disease Diagnosis
viome.com

See what CB Insights has to offer

Total Raised

$84.96M

Investors Count

9

Deal Terms

1

Viome Funding, Viome Valuation & Viome Revenue

5 Fundings

Viome's latest funding round was a Series C - II for $3M on February 11, 2021.

Date

Round

Amount

Investors

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Revenue

Sources

2/11/2021

Series C - II

$3M

$0.00B

((9.99x))

FY 1234

1

11/27/2019

Series C

$99M

$0.00B

((9.99x))

FY 1234

10

4/17/2019

Series B

$99M

$0.00B

((9.99x))

FY 1234

10

7/3/2018

Series A - II

$99M

$0.00B

((9.99x))

FY 1234

10

7/28/2017

Series A

$99M

$0.00B

((9.99x))

FY 1234

10

Date

2/11/2021

11/27/2019

4/17/2019

7/3/2018

7/28/2017

Round

Series C - II

Series C

Series B

Series A - II

Series A

Amount

$3M

$99M

$99M

$99M

$99M

Investors

Valuation

Revenue

$0.00B

((9.99x))

FY 1234

$0.00B

((9.99x))

FY 1234

$0.00B

((9.99x))

FY 1234

$0.00B

((9.99x))

FY 1234

$0.00B

((9.99x))

FY 1234

Sources

1

10

10

10

10

Viome Deal Terms

1 Deal Term

Viome's deal structure is available for 1 funding round, including their Series A from July 28, 2017.

Round

Series A

Funding Date

Pre-Money Valuation

Post-Money Valuation

Amount Raised

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

Board Voting

Par Value

Round

Funding Date

Pre-Money Valuation

Post-Money Valuation

Amount Raised

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

Board Voting

Par Value

Series A

Viome Investors

9 Investors

Viome has 9 investors. AEA Investors invested in Viome's Series C - II funding round.

First funding

Last Funding

Investor

Rounds

Board Seats

Type

Location

2/11/2021

2/11/2021

1
Series C - II

Private Equity

New York

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Venture Capital

California

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Corporation

Florida

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Venture Capital

New York

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Angel Investor (Individual)

California

First funding

2/11/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Last Funding

2/11/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Investor

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Rounds

1
Series C - II

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Board Seats

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Type

Private Equity

Venture Capital

Corporation

Venture Capital

Angel Investor (Individual)

Location

New York

California

Florida

New York

California

Viome Acquisitions

1 Acquisition

Viome acquired 1 company. Their latest acquisition was Habit on February 06, 2019.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

2/6/2019

Series A

$32M

Acquired

3

Date

2/6/2019

Investment Stage

Series A

Companies

Valuation

Total Funding

$32M

Note

Acquired

Sources

3

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.